In the last trading session, 2.17 million shares of the Terns Pharmaceuticals Inc (NASDAQ:TERN) were traded, and its beta was -0.41. Most recently the company’s share price was $9.41, and it changed around $0.46 or 5.08% from the last close, which brings the market valuation of the company to $774.35M. TERN currently trades at a discount to its 52-week high of $11.40, offering almost -21.15% off that amount. The share price’s 52-week low was $3.26, which indicates that the current value has risen by an impressive 65.36% since then. We note from Terns Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 5.5 million shares, with the 3-month average coming to 1.88 million.
Terns Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 2 recommended TERN as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Terns Pharmaceuticals Inc is expected to report earnings per share of -0.34 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information
Instantly TERN has showed a green trend with a performance of 5.08% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 11.40 on recent trading dayincreased the stock’s daily price by 17.46%. The company’s shares are currently up 44.99% year-to-date, but still up 3.18% over the last five days. On the other hand, Terns Pharmaceuticals Inc (NASDAQ:TERN) is 40.03% up in the 30-day period. We can see from the shorts that 2.66 million shares have been sold at a short interest cover period of 2.63 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 21.58% from its current value. Analyst projections state that TERN is forecast to be at a low of $7 and a high of $26.
Terns Pharmaceuticals Inc (TERN) estimates and forecasts
Terns Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 30.69 percent over the past six months and at a -2.36% annual growth rate that is well below the industry average of 17.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 19.00% in revenue this quarter, and will report a decrease of -17.20% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.40%.
TERN Dividends
Terns Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in October.
Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.25% of Terns Pharmaceuticals Inc shares, and 84.41% of them are in the hands of institutional investors. The stock currently has a share float of 85.47%. Terns Pharmaceuticals Inc stock is held by 175.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 10.2326% of the shares, which is about 7.62 million shares worth $51.89 million.
VIVO CAPITAL, LLC, with 8.3038% or 6.18 million shares worth $42.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
